Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £303.68B | 28.9x | 1.08 | GBX 6,832.78 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie Inc | London | Healthcare | Pharmaceuticals | £264.22B | 64.4x | -2.9 | GBX 15,727.66 | 6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £202.83B | 22.9x | -6.4 | GBX 26,843.64 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £202.83B | 22.9x | -6.38 | GBX 25,144.90 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £201.13B | 20.6x | 0.12 | GBX 8,022.14 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £176.58B | 33.7x | 3.36 | GBX 11,344 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Novartis | London | Healthcare | Pharmaceuticals | £169.03B | 12.1x | 0.13 | GBX 8,490.16 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £109.10B | 22.4x | -0.55 | GBX 8,694.55 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £97.44B | 965.3x | -9.32 | GBX 7,870.64 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £57.37B | 22.8x | -0.37 | GBX 1,405 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £53.46B | 23.7x | -3.31 | GBX 12,284.04 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £34.01B | 28.4x | -9.51 | GBX 374.70 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.8% Upside | Upgrade to Pro+ | |
UCB L | London | Healthcare | Pharmaceuticals | £29.91B | 148.9x | -5.44 | GBX 15,740.63 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £17.73B | -24.1x | -0.31 | GBX 1,803.11 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £16.91B | 13x | 1.31 | GBX 11,736.25 | 100,000% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £16.82B | -2,379.2x | 25.63 | GBX 3,861.10 | 52.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £10.04B | 28.7x | 2.13 | GBX 4,947.06 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £8.39B | 32.7x | 2.45 | GBX 2,454.95 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £8.21B | 14.5x | 0.29 | GBX 9,993.59 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £6.14B | 22.1x | 0.24 | GBX 4,360.23 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £5.09B | 22x | 0.22 | GBX 2,292 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.8% Upside | Upgrade to Pro+ | |
Grifols Pref | London | Healthcare | Pharmaceuticals | £4.75B | 35x | GBX 557.57 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Grifols | London | Healthcare | Pharmaceuticals | £4.75B | 35x | GBX 700.51 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
H Lundbeck L | London | Healthcare | Pharmaceuticals | £4.63B | 15.4x | 1.58 | GBX 493.28 | -74.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £4.06B | 45.9x | 0.47 | GBX 1,824.32 | 8.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £3.80B | 8.8x | 0.03 | GBX 2,087.91 | 102.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | £2.66B | 39.9x | -3.19 | GBX 19,450.20 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | £2.55B | 128.3x | -2.82 | GBX 4,341.69 | 14.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | £2.27B | 19.2x | 0.92 | GBX 27,105.15 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | £1.91B | -56.3x | 6.28 | GBX 219.50 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Almirall | London | Healthcare | Pharmaceuticals | £1.70B | -45.2x | GBX 793.30 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Pharma Mar | London | Healthcare | Pharmaceuticals | £1.34B | 2,630x | GBX 7,694.77 | 7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Indivior PLC | London | Healthcare | Pharmaceuticals | £1.19B | -541x | -5.03 | GBX 957.50 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.3% Upside | Upgrade to Pro+ | |
Fagron NV | London | Healthcare | Pharmaceuticals | £1.17B | 18.1x | 1.12 | GBX 1,602.48 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cosmo Pharmas | London | Healthcare | Pharmaceuticals | £937.85M | 16.1x | 0.03 | GBX 5,830.57 | 20.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faes Farma | London | Healthcare | Pharmaceuticals | £920.77M | 11.3x | GBX 296.11 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biogaia AB | London | Healthcare | Pharmaceuticals | £890.92M | 36.4x | -1.52 | GBX 882.91 | -76.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Uniphar | London | Healthcare | Pharmaceuticals | £537.76M | 15.9x | 10.21 | GBX 197.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medincell | London | Healthcare | Pharmaceuticals | £386.05M | -14.6x | 1.66 | GBX 1,319.10 | 80.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alliance Pharma | London | Healthcare | Pharmaceuticals | £332.45M | -9.9x | 0.67 | GBX 61.30 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.1% Upside | Upgrade to Pro+ | |
Niox PLC | London | Healthcare | Pharmaceuticals | £238.79M | 21.4x | 1.88 | GBX 60 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.3% Upside | Upgrade to Pro+ | |
Beximco Pharma. | London | Healthcare | Pharmaceuticals | £222.62M | 5.4x | 0.22 | GBX 38.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Santhera Pharmas Holding | London | Healthcare | Pharmaceuticals | £190.89M | 2.9x | 0.02 | GBX 1,512.94 | 75.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Animalcare | London | Healthcare | Pharmaceuticals | £164.18M | 7.9x | 0.03 | GBX 237 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.8% Upside | Upgrade to Pro+ | |
Photocure | London | Healthcare | Pharmaceuticals | £110.23M | 111.8x | 0.72 | GBX 401.91 | 7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
bluebird bio | London | Healthcare | Pharmaceuticals | £61.10M | -0.2x | 0 | GBX 642.25 | 100,000% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Venture Life Group | London | Healthcare | Pharmaceuticals | £43.82M | 57.1x | 0.33 | GBX 34.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eco Animal | London | Healthcare | Pharmaceuticals | £43.73M | 64.5x | 0.47 | GBX 64.50 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kala Pharmaceuticals | London | Healthcare | Pharmaceuticals | £33.71M | -0.8x | -0.02 | GBX 737.34 | 33% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRUSHMETRIC | Aquis Exchange | Healthcare | Pharmaceuticals | £30.16M | -4.4x | GBX 0.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |